Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO-Ilb trial

Journal of the American College of Cardiology

Volumn 31, Issue 7, 1998, Pages 1493-1498

  Metz, Brian K ^a   White, Harvey D ^b   Granger, Christopher B ^c   Simes, R John ^d   Armstrong, Paul W ^e   Hirsh, Jack ^f   Fuster, Valentin ^g   MacAulay, Cynthia M ^c   Califf, Robert M ^c   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b GREEN LANE HOSPITAL   (New Zealand)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF ALBERTA   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; STREPTOKINASE; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG COST; DRUG POTENTIATION; FEMALE; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTITHROMBINS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; PROSPECTIVE STUDIES; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 7144253804     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00138-7     Document Type: Article

References (29)

1. Becker R.C., Gore J.M., Lambrew C., et al. A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol. 27:1996;1321-1326.
2. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
3. Weitz J.I., Huboda M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:1990;385-391.
4. Lee L.V. Initial experience with hirudin and streptokinase in acute myocardial infarction results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial . Am J Cardiol. 75:1995;7-13.
5. Molhoek G.P., Laarman G., Lok D.J., et al. Effects of recombinant hirudin on early and late coronary patency in acute myocardial infarction patients treated with streptokinase (the HIT-SK study). Circulation. 92:(Suppl I):1995;415-416.
6. White HD, Aylward PE, Frey M, et al., on behalf of the Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. A randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction. Circulation 1997;96:2155-61.
7. Theroux P., Perez-Villa F., Waters D., Lesperance J., Shabari F., Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation. 91:1995;2132-2139.
8. Metz B.K., Topol E.J. Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction. Biomed Pharmacother. 50:1996;243-253.
9. Freudenberger R., Fuster V. Acute coronary syndromes thrombosis and thrombolysis . Smith T.W. Cardiovascular Therapeutics A Companion to Braunwald's Heart Disease . 1996;455-469 W.B. Saunders, Philadelphia.
10. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
11. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 336:1997;1621-1628.
12. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622.
13. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 90:1994;1631-1637.
14. Antman E.M. Hirudin in acute myocardial infarction safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial . Circulation. 90:1994;1624-1630.
15. Neuhaus K.-L., van Essen R., Tebbe U., et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK) . Circulation. 90:1994;1638-1642.
16. Brommer E.J.P., Meijer P. Thrombin generation induced by the intrinsic or extrinsic coagulation pathway is accelerated by streptokinase, independently of plasminogen. Thromb Haemostas. 70:1993;995-997.
17. Granger C.B., Becker R., Tracy R.P., et al. Thrombin generation, inhibition, and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin results from the GUSTO-I trial . J Am Coll Cardiol. 31:1998;497-505.
18. Antman E.M. Hirudin in acute myocardial infarction Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial . Circulation. 94:1996;911-921.
19. Owen J., Friedman K.D., Grossman B.A., Wilkins C., Berke A.D., Powers E.R. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood. 72:1988;616-620.
20. Simes R.J., Granger C.B., Antman E.M., Califf R.M., Braunwald E., Topol E.J. Impact of hirudin versus heparin on mortality and (re)infarction in patients with acute coronary syndromes a prospective meta-analysis of the GUSTO-IIb and TIMI 9b trials [abstract] . Circulation. 94:(Suppl I):1996;I-430.
21. Rao A.K., Sun L., Chesebro J.H., et al. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide a and prothrombin fragment F1.2 in unstable angina A multicenter trial . Circulation. 94:1996;2389-2395.
22. GISSI-2 a factorial randomised trial of t-PA versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction . Lancet. 336:1990;65-71.
23. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between t-PA and streptokinase with or without heparin. Lancet. 336:1990;71-75.
24. ISIS-3 a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction . Lancet. 339:1992;753-770.
25. O'Donnell C.J., Ridker P.M., Hebert P.R., Hennekens C.H. Antithrombotic therapy for acute myocardial infarction. J Am Coll Cardiol. 25:(Suppl S):1995;23S-29S.
26. White H.D., Yusuf S. Issues regarding the use of heparin following streptokinase therapy. J Thromb Thrombol. 2:1995;5-10.
27. Collins R., MacMahon S., Flather M., et al. Clinical effects of anticoagulation therapy in suspected acute myocardial infarction systematic overview of randomised trials . BMJ. 313:1996;652-659.
28. Collins R., Peto R., Baigent C., Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 336:1997;847-860.
29. Ryan T.J., Anderson J.L., Antman E.M., et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) . J Am Coll Cardiol. 28:1996;1328-1428.